Pharmaceutical Companies

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.

MIEBO contains the active ingredient perfluorohexyloctane and is the first prescription eye drop designed to target tear evaporation directly, one of the primary causes of dry eye disease.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.

NICE recommended Imfinzi for adults whose stomach cancer has not spread extensively and can be removed through surgery, including gastric and gastro-oesophageal junction cancers that physicians frequently diagnose at advanced stages.

The acquisition includes MacroGenics’ biologics drug substance manufacturing facility in Rockville, Maryland, as well as a warehousing center in Frederick, Maryland, located about 30 miles away.

The next phase will focus on installing and validating fill-and-finish equipment, strengthening quality control systems, building specialized workforce capacity, and preparing for compliant vaccine manufacturing.

The pharmaceutical company submitted bids across several critical childhood immunisation categories, including the Pneumococcal Conjugate Vaccine (PCV10), Rotavirus vaccine, and paediatric Hepatitis B vaccine.